COVID-19 mRNA疫苗接种后急性自身免疫性肝炎:一项基于新加坡电子健康记录的人群研究
研究利用新加坡全国电子健康记录,采用观察-预期比(O/E)和自我对照病例系列(SCCS)分析,评估COVID-19 mRNA疫苗接种后需住院的急性自身免疫性肝炎(AAIH)风险。2019年1月1日至2023年2月28日期间共76例符合AAIH定义,其中6例在接种后42天内发病,均为40岁及以上女性。O/E分析中40岁及以上女性21天和42天率比分别为1.12(95%CI 0.14-9.40)和1.06(95%CI 0.24-4.74),SCCS分析未观察到统计学显著增加。作者认为mRNA疫苗接种似乎与AAIH住院风险增加无关,但需更大规模研究确认。
要点
- 76例AAIH中6例在mRNA疫苗接种后42天内发病,均为40岁及以上女性。
- O/E分析40岁及以上女性21天率比1.12(95%CI 0.14-9.40),42天率比1.06(95%CI 0.24-4.74)。
- SCCS分析未观察到接种后21天和42天AAIH发病率统计学显著增加。
核心结论
- 研究结果表明COVID-19 mRNA疫苗接种似乎与人群中需住院的AAIH风险增加无关,但需更大规模研究确认。
研究设计与样本
- 全国性研究,采用观察-预期比(O/E)和自我对照病例系列(SCCS)分析,纳入2019年1月1日至2023年2月28日期间需住院的急性自身免疫性肝炎(AAIH)病例。
- 病例定义需满足肝炎相关症状(发热、乏力、黄疸或腹痛)在入院前3个月内报告、肝功能检查异常(ALT或AST大于实验室参考范围上限三倍),以及活检符合AIH特征或未活检者对激素治疗有反应。
- 共76例患者符合AAIH病例定义,其中6例估计在COVID-19 mRNA疫苗接种后42天内发病。
主要发现
- 6例接种后42天内发病的AAIH患者均为40岁及以上女性。
- O/E分析中,主要队列40岁及以上女性接种后21天AAIH率比为1.12(95%CI 0.14-9.40),42天率比为1.06(95%CI 0.24-4.74)。
- SCCS分析中,主要队列和补充队列接种后21天和42天AAIH发病率均未观察到统计学显著增加,40岁及以上女性亚组分析同样未观察到统计学显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需更大规模研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reports of coronavirus disease 2019 (COVID-19) vaccine-induced autoimmune hepatitis (AIH) have been largely limited to case reports and case series. To further investigate the association between COVID-19 mRNA vaccination and AIH, we conducted a nationwide study using observed-over-expected (O/E) and Self-Controlled Case Series (SCCS) analyses for acute presentations of AIH (AAIH) warranting admission. Patients were included if they had one or more of the following hepatitis-related signs and symptoms (fever, lethargy, jaundice or abdominal pain) reported up to 3 months prior to admission, deranged liver function tests [alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of laboratory reference ranges], as well as biopsy results characteristic of AIH or response to steroid treatment for cases which did not undergo biopsy. Seventy-six patients fulfilled our case definition of AAIH within the study period from 1 January 2019 to 28 February 2023, with 6 patients having an estimated onset of AAIH within 42 days of COVID-19 mRNA vaccination. All 6 patients were females aged 40 years and above. In the O/E analysis, the rate ratios of AAIH among females aged 40 years and above in the primary cohort were 1.12 (95% confidence interval (CI) 0.14-9.40) and 1.06 (95% CI 0.24-4.74) in the 21 days and 42 days following vaccination respectively. In the SCCS analysis, we did not observe any statistically significant increase in incidence of AAIH in the 21 and 42 days following COVID-19 mRNA vaccination for both the primary and supplementary cohorts, as well as in the subgroup analysis involving females aged 40 years and above. Our findings suggest that COVID-19 mRNA vaccination does not appear to be associated with increased risk of AAIH requiring admissions in the population, although larger studies are required to confirm these findings.
引用
- Ng AJJ, Teo DCH, Dorajoo SR, et al. Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore. Vaccine. 2024. PMID: 39454292. doi:10.1016/j.vaccine.2024.126462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。